Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma

Addition of IL-4 (1,000 U/ml) to either high or low concentrations of IL-2 augmented tumor-infiltrating lymphocytes (TIL) growth from human melanoma. Weekly restimulation with irradiated tumor cells in conjunction with IL-4 allowed enhanced growth of TIL. With low-dose IL- 2 (10 U/ml) and IL-4, expanded TIL had little cytolytic activity against Daudi or allogeneic tumors. Further, IL-4 augmented the total lytic activity against autologous tumors in most cases. With high-dose IL-2 (1,000 U/ml), IL-4 addition decreased nonspecific killing activity against Daudi or allogeneic melanomas in many cases, and reciprocally augmented cytolytic activity against the autologous melanoma in many cases. This suggests the possible use of IL-4 in cancer therapy, especially in adoptive cellular immunotherapy using TIL or in conjunction with IL-2 administration.

[1]  C. Figdor,et al.  IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. , 1988, Journal of immunology.

[2]  W. Linehan,et al.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Puri,et al.  Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. , 1988, Journal of the National Cancer Institute.

[4]  K. Arai,et al.  Molecular Biology of Interleukin 4 and Interleukin 5 Genes and Biology of their Products that Stimulate B Cells, T Cells and Hemopoietic Cells , 1988, Immunological reviews.

[5]  W. Paul,et al.  Heterogeneity of helper/inducer T lymphocytes. I. Lymphokine production and lymphokine responsiveness , 1987, The Journal of experimental medicine.

[6]  K. Grabstein,et al.  Regulation of cytolytic cell populations from human peripheral blood by B cell stimulatory factor 1 (interleukin 4) , 1987, The Journal of experimental medicine.

[7]  S. Rosenberg,et al.  Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells , 1987, The Journal of experimental medicine.

[8]  S. Rosenberg,et al.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. , 1987, Journal of immunological methods.

[9]  K. Arai,et al.  Recombinant interleukin 4 promotes the growth of human T cells. , 1987, Journal of immunology.

[10]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[11]  S. Rosenberg,et al.  Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. , 1987, Journal of immunology.

[12]  W. Paul,et al.  B-cell stimulatory factor-1/interleukin 4. , 1987, Annual review of immunology.

[13]  J. Ashwell,et al.  Proliferation of T lymphocytes in response to interleukin 2 varies with their state of activation. , 1986, Journal of Immunology.

[14]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.